ArticleFrontiers in psychiatry2025
Case report: Twice-daily 15mA transcranial alternating current stimulation for adolescent major depressive disorder with suicidal ideation.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adolescent major depressive disorder with suicidal ideation (MDD-SI) poses significant treatment challenges and carries substantial mortality risk, while existing interventions often demonstrate limited acute efficacy for suicidal ideation (SI). Methods: This two-week prospective case series investigated the feasibility and preliminary therapeutic effects of high-frequency transcranial alternating current stimulation (tACS) administered twice daily. Seven adolescents with MDD-SI underwent 40-minute tACS sessions (77.5 Hz, 15 mA) twice-daily over a two weeks for a total of 20 sessions, in conjunction with stable pharmacotherapy. Results: The accelerated tACS protocol was well-tolerated with no adverse events. It demonstrated significant reductions in both depressive symptoms and SI within two weeks (all Conclusion: These preliminary findings suggest the potential of accelerated high-frequency tACS as a potential crisis intervention for adolescent MDD-SI, while highlighting the need for controlled clinical trials to establish efficacy and optimize stimulation parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.